U.S. and Indian officials gathered in New
Delhi last week to start delicate negotiations over how India will separate its vast nuclear establishment into military and civilian components. In July, the allies agreed to share nuclear technology and expertise, an accord that promises to make India, which has refused to sign the Nuclear Nonproliferation Treaty, a fullblown member of the atomic club.
But which Indian facilities and researchers will come in from the cold remains a thorny issue. "There is an internal debate going on within India about where to go with this," says Harvard nonproliferation expert Matthew Bunn. Although some facilities-such as the Bhabha Atomic Research Centre in Mumbai-would likely stay secret, there will be a tug of war over others, including the fast breeder facility in Kalpakkam. Under the new agreement, facilities declared civilian would come under international safeguards and enable scientists to collaborate. U.S. envoy Nicholas Burns, who was in Delhi, warned that the separation plan could take years to implement. Finalizing the much-touted nuclear deal itself will require a series of changes to U.S. law and international rules, which the United States and India hope to see happen by early next year.
-RICHARD STONE
U.S. Restricts 1918 Flu Virus
As expected, the federal government has declared the resurrected 1918 pandemic influenza virus a select agent and restricted its use.The government is also exploring whether other viruses containing any genes from the 1918 flu should be controlled. Three weeks ago, researchers at the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia, and elsewhere reported that they had reconstructed the complete 1918 virus, which killed up to 50 million people (Science, 7 October, p. 28 The map allows gene hunters to get away with less (and thus cheaper) DNA sequencing while still, it's hoped, homing in on disease genes. The current HapMap-a finerresolution version will come out next year-includes more than 1 million SNPs drawn from the DNA of 269 individuals from four different populations, because haplotype frequencies vary based on evolutionary history. An international consortium announced the draft's completion at the annual meeting of the American Society of Human Genetics in Salt Lake City, Utah, this week; the map was also published in this week's issue of Nature. (The U.S. National Institutes of Health contributed more than $60 million toward the map's $138 million price tag; funds also came from the United Kingdom, Japan, China, and Canada.) Already, data from the map, which are freely available online, are helping pave the way toward finding genes involved in macular degeneration, dyslexia, and hypertension, among other disorders. The HapMap "opens up a really powerful new approach [for finding disease genes], but an unfamiliar one," says Collins. Geneticists aren't necessarily accustomed to a genehunting method based on population genetics, Collins explains, so they may need some encouragement to use the HapMap.
David Altshuler of the Broad Institute in Cambridge, Massachusetts, a leader of the HapMap project along with Peter Donnelly of Oxford, agrees. "When you present people with the sort of data they haven't had before, you end up with a lot of foment and confusion and excitement," Altshuler says. More than 500 scientists signed up for a session in Salt Lake City on how to glean the most from the map.
The Nature HapMap paper confirmed that, as hoped, a select set of SNPs reliably defines the DNA surrounding them, making it possible to locate relevant genes by comparing haplotype patterns in different groups. It also offers insights, say its more than 200 co-authors, into how evolutionary pressure shaped the genome. But concern lingers about how the HapMap will perform in the hunt for disease genes. Last week, two German researchers published a paper in the American Journal of Human Genetics in which they showed that selecting a different set of SNPs turns up somewhat different haplotypes. The worry is that gene-hunting on different haplotype maps-derived from different sets of SNPs-might lead to divergent results, says co-author Michael Nothnagel, a mathematician at Christian-Albrechts University in Kiel, Germany.
So far, however, there's no evidence to support that contention, say Altshuler and David Cox, chief scientific officer of Perlegen Sciences in Mountain View, California. Cox led a private initiative that published its map in Science in February. Although the haplotypes identified in that map, of 71 Americans of Asian, European, and African ancestry, differ somewhat from those in the international consortium map, both should point gene hunters to similar DNA regions, says Cox. Exact haplotype boundaries don't seem to matter much, adds Altshuler, who compares a haplotype block with a mountain: No one agrees precisely on where one begins, but there's no dispute that it's there.
-JENNIFER COUZIN
